Chicago Capital LLC cut its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 97.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,726 shares of the medical device company's stock after selling 949,881 shares during the period. Chicago Capital LLC's holdings in Tandem Diabetes Care were worth $397,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its holdings in Tandem Diabetes Care by 163.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares during the last quarter. US Bancorp DE boosted its holdings in Tandem Diabetes Care by 15.2% in the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock valued at $1,394,000 after acquiring an additional 5,108 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in Tandem Diabetes Care by 22.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock valued at $236,000 after acquiring an additional 1,184 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after acquiring an additional 77,451 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Tandem Diabetes Care by 763.3% in the first quarter. GAMMA Investing LLC now owns 42,190 shares of the medical device company's stock valued at $808,000 after acquiring an additional 37,303 shares during the last quarter.
Analyst Upgrades and Downgrades
Several analysts recently commented on the company. Sanford C. Bernstein cut Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $35.00 to $25.00 in a report on Friday, February 28th. Stifel Nicolaus cut their price target on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Barclays cut their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Robert W. Baird cut their price target on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a report on Thursday, May 1st. Finally, Wall Street Zen cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $33.43.
Check Out Our Latest Stock Report on TNDM
Tandem Diabetes Care Stock Down 0.9%
Shares of NASDAQ:TNDM traded down $0.19 during trading on Friday, reaching $20.22. 1,120,610 shares of the stock were exchanged, compared to its average volume of 1,498,784. The company has a debt-to-equity ratio of 1.99, a current ratio of 2.30 and a quick ratio of 1.81. Tandem Diabetes Care, Inc. has a 1-year low of $15.75 and a 1-year high of $48.24. The stock has a fifty day moving average of $20.25 and a two-hundred day moving average of $26.09. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -7.27 and a beta of 1.52.
Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The firm had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative return on equity of 57.33% and a negative net margin of 18.71%. Tandem Diabetes Care's revenue for the quarter was up 22.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.65) earnings per share. Research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.
Tandem Diabetes Care Company Profile
(
Free Report)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
See Also
Before you consider Tandem Diabetes Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.
While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
